| Gender Preference | None |
| Age Group | 1 - 99 years |
| Research Start Date | April 11, 2011 |
| Research End Date | February 4, 2014 |
| Principal Investigator | Sif Hansdottir, MD |
| Description |
Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution
Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.
Please refer to www.clinicaltrials.gov for more information identifier NCT01266265 |
| Contact Info | Pulmonary Hypertension Program
Cynthia Larew RN 319-356-1028 pager # 2123
cynthia-larew@uiowa.edu |
| Keywords | span itemProp='description'>Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso ; |